These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38858349)

  • 1. Pharmacological modulation of developmental and synaptic phenotypes in human SHANK3 deficient stem cell-derived neuronal models.
    Thibaudeau A; Schmitt K; François L; Chatrousse L; Hoffmann D; Cousin L; Weiss A; Vuidel A; Jacob CB; Sommer P; Benchoua A; Wilbertz JH
    Transl Psychiatry; 2024 Jun; 14(1):249. PubMed ID: 38858349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients.
    Shcheglovitov A; Shcheglovitova O; Yazawa M; Portmann T; Shu R; Sebastiano V; Krawisz A; Froehlich W; Bernstein JA; Hallmayer JF; Dolmetsch RE
    Nature; 2013 Nov; 503(7475):267-71. PubMed ID: 24132240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications.
    Delling JP; Boeckers TM
    J Neurodev Disord; 2021 Nov; 13(1):55. PubMed ID: 34784886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disrupted extracellular matrix and cell cycle genes in autism-associated Shank3 deficiency are targeted by lithium.
    Ioannidis V; Pandey R; Bauer HF; Schön M; Bockmann J; Boeckers TM; Lutz AK
    Mol Psychiatry; 2024 Mar; 29(3):704-717. PubMed ID: 38123724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autism-associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons.
    Yi F; Danko T; Botelho SC; Patzke C; Pak C; Wernig M; Südhof TC
    Science; 2016 May; 352(6286):aaf2669. PubMed ID: 26966193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice.
    Vicidomini C; Ponzoni L; Lim D; Schmeisser MJ; Reim D; Morello N; Orellana D; Tozzi A; Durante V; Scalmani P; Mantegazza M; Genazzani AA; Giustetto M; Sala M; Calabresi P; Boeckers TM; Sala C; Verpelli C
    Mol Psychiatry; 2017 May; 22(5):689-702. PubMed ID: 27021819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental social communication deficits in the Shank3 rat model of phelan-mcdermid syndrome and autism spectrum disorder.
    Berg EL; Copping NA; Rivera JK; Pride MC; Careaga M; Bauman MD; Berman RF; Lein PJ; Harony-Nicolas H; Buxbaum JD; Ellegood J; Lerch JP; Wöhr M; Silverman JL
    Autism Res; 2018 Apr; 11(4):587-601. PubMed ID: 29377611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased rates of cerebral protein synthesis in Shank3 knockout mice: Implications for a link between synaptic protein deficit and dysregulated protein synthesis in autism spectrum disorder/intellectual disability.
    Torossian A; Saré RM; Loutaev I; Smith CB
    Neurobiol Dis; 2021 Jan; 148():105213. PubMed ID: 33276083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.
    Costales JL; Kolevzon A
    Neurotherapeutics; 2015 Jul; 12(3):620-30. PubMed ID: 25894671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 29 Mainland Chinese cohort of patients with Phelan-McDermid syndrome: genotype-phenotype correlations and the role of SHANK3 haploinsufficiency in the important phenotypes.
    Xu N; Lv H; Yang T; Du X; Sun Y; Xiao B; Fan Y; Luo X; Zhan Y; Wang L; Li F; Yu Y
    Orphanet J Rare Dis; 2020 Nov; 15(1):335. PubMed ID: 33256793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHANK3 deficiency leads to myelin defects in the central and peripheral nervous system.
    Malara M; Lutz AK; Incearap B; Bauer HF; Cursano S; Volbracht K; Lerner JJ; Pandey R; Delling JP; Ioannidis V; Arévalo AP; von Bernhardi JE; Schön M; Bockmann J; Dimou L; Boeckers TM
    Cell Mol Life Sci; 2022 Jun; 79(7):371. PubMed ID: 35726031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of two Shank3 and the Cacna1c mouse models of autism spectrum disorder.
    Kabitzke PA; Brunner D; He D; Fazio PA; Cox K; Sutphen J; Thiede L; Sabath E; Hanania T; Alexandrov V; Rasmusson R; Spooren W; Ghosh A; Feliciano P; Biemans B; Benedetti M; Clayton AL
    Genes Brain Behav; 2018 Jan; 17(1):4-22. PubMed ID: 28753255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by
    De Rubeis S; Siper PM; Durkin A; Weissman J; Muratet F; Halpern D; Trelles MDP; Frank Y; Lozano R; Wang AT; Holder JL; Betancur C; Buxbaum JD; Kolevzon A
    Mol Autism; 2018; 9():31. PubMed ID: 29719671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.
    Harony-Nicolas H; De Rubeis S; Kolevzon A; Buxbaum JD
    J Child Neurol; 2015 Dec; 30(14):1861-70. PubMed ID: 26350728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An IGFBP2-derived peptide promotes neuroplasticity and rescues deficits in a mouse model of Phelan-McDermid syndrome.
    Burgdorf JS; Yoon S; Dos Santos M; Lammert CR; Moskal JR; Penzes P
    Mol Psychiatry; 2023 Mar; 28(3):1101-1111. PubMed ID: 36481930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial 22q13 deletions not involving SHANK3 gene: a new contiguous gene syndrome.
    Disciglio V; Lo Rizzo C; Mencarelli MA; Mucciolo M; Marozza A; Di Marco C; Massarelli A; Canocchi V; Baldassarri M; Ndoni E; Frullanti E; Amabile S; Anderlid BM; Metcalfe K; Le Caignec C; David A; Fryer A; Boute O; Joris A; Greco D; Pecile V; Battini R; Novelli A; Fichera M; Romano C; Mari F; Renieri A
    Am J Med Genet A; 2014 Jul; 164A(7):1666-76. PubMed ID: 24700646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zinc deficiency and low enterocyte zinc transporter expression in human patients with autism related mutations in SHANK3.
    Pfaender S; Sauer AK; Hagmeyer S; Mangus K; Linta L; Liebau S; Bockmann J; Huguet G; Bourgeron T; Boeckers TM; Grabrucker AM
    Sci Rep; 2017 Mar; 7():45190. PubMed ID: 28345660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe white matter damage in SHANK3 deficiency: a human and translational study.
    Jesse S; Müller HP; Schoen M; Asoglu H; Bockmann J; Huppertz HJ; Rasche V; Ludolph AC; Boeckers TM; Kassubek J
    Ann Clin Transl Neurol; 2020 Jan; 7(1):46-58. PubMed ID: 31788990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency.
    Bidinosti M; Botta P; Krüttner S; Proenca CC; Stoehr N; Bernhard M; Fruh I; Mueller M; Bonenfant D; Voshol H; Carbone W; Neal SJ; McTighe SM; Roma G; Dolmetsch RE; Porter JA; Caroni P; Bouwmeester T; Lüthi A; Galimberti I
    Science; 2016 Mar; 351(6278):1199-203. PubMed ID: 26847545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Brazilian cohort of individuals with Phelan-McDermid syndrome: genotype-phenotype correlation and identification of an atypical case.
    Samogy-Costa CI; Varella-Branco E; Monfardini F; Ferraz H; Fock RA; Barbosa RHA; Pessoa ALS; Perez ABA; Lourenço N; Vibranovski M; Krepischi A; Rosenberg C; Passos-Bueno MR
    J Neurodev Disord; 2019 Jul; 11(1):13. PubMed ID: 31319798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.